Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Beijing's BeiGene Raises $200 Million in a Secondary Offering

publication date: Nov 22, 2016
BeiGene, a Beijing novel oncology biopharma, completed a $200 million secondary offering last week, up from its initial target of $175 million. The $200 million included $15 million from selling shareholders. In February, BeiGene raised $182 million in a NASDAQ IPO, and it reported $200 million in cash at the end of the third quarter. BeiGene is currently running clinical trials on four novel cancer drug candidates, and its costs have risen as a result: the company reported a loss of $80 million in the first nine months of 2017. More details....

Stock Symbol: (NSDQ: BGNE)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital